Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T. Rollin J, et al. Among authors: boisdron celle m. Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30. Pharmacogenomics. 2015. PMID: 26615857 Free article. Clinical Trial.
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
Morel A, Boisdron-Celle M, Fey L, Lainé-Cessac P, Gamelin E. Morel A, et al. Clin Biochem. 2007 Jan;40(1-2):11-7. doi: 10.1016/j.clinbiochem.2006.07.012. Epub 2006 Sep 1. Clin Biochem. 2007. PMID: 17046731
[Pharmacogenetics of anti-cancer drugs].
Gamelin E, Boisdron-Celle M, Morel A, Capitain O. Gamelin E, et al. Ann Pharm Fr. 2007 Nov;65(6):390-401. doi: 10.1016/s0003-4509(07)74198-6. Ann Pharm Fr. 2007. PMID: 18079671 Review. French.
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J. Gamelin E, et al. J Clin Oncol. 1998 Apr;16(4):1470-8. doi: 10.1200/JCO.1998.16.4.1470. J Clin Oncol. 1998. PMID: 9552054 Clinical Trial.
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E, Boisdron-Celle M, Guérin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J. Gamelin E, et al. J Clin Oncol. 1999 Apr;17(4):1105. doi: 10.1200/JCO.1999.17.4.1105. J Clin Oncol. 1999. PMID: 10561167 Clinical Trial.
72 results